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A prospective phase I dose-escalation trial
of stereotactic ablative radiotherapy (SABR)
as an alternative to cytoreductive
nephrectomy for inoperable patients with
metastatic renal cell carcinoma
Rohann J. M. Correa1, Belal Ahmad1, Andrew Warner1, Craig Johnson1, Mary J. MacKenzie2, Stephen E. Pautler3,4,
Glenn S. Bauman1, George B. Rodrigues1,5 and Alexander V. Louie1,5*
Abstract
Background: Cytoreductive nephrectomy is thought to improve survival in metastatic renal cell carcinoma (mRCC).
As many patients are ineligible for major surgery, we hypothesized that SABR could be a safe alternative.
Methods: In this dose-escalation trial, inoperable mRCC patients underwent SABR targeting the entire affected kidney.
Toxicity (CTCAE v3.0), quality of life (QoL), renal function, and tumour response (RECIST v1.0) were assessed.
Results: Twelve patients of mostly intermediate (67%) or poor (25%) International Metastatic Renal Cell Carcinoma Database
Consortium (IMDC) prognostic class, median KPS of 70%, and median tumour size of 8.7 cm (range: 4.8–13.8) were enrolled
in successive dose cohorts of 25 (n = 3), 30 (n = 6), and 35 Gy (n = 3) in 5 fractions. SABR was well tolerated with 3 grade 3
events: fatigue (2) and bone pain (1). QoL decreased for physical well-being (p = 0.016), but remained unchanged in other
domains. SABR achieved a median tumour size reduction of − 17.3% (range: + 5.3 to − 54.4) at 5.3 months. All patients
progressed systemically and median OS was 6.7 months. Crude median follow-up was 5.8 months.
Conclusions: In non-operable mRCC patients, renal-ablative SABR to 35 Gy in 5 fractions yielded acceptable toxicity,
renal function preservation, and stable QoL. SABR merits further prospective investigation as an alternative to cytoreductive
nephrectomy.
Trial Registration: ClinicalTrials.gov NCT02264548. Registered July 22 2014 – Retrospectively registered: https://clinicaltrials.
gov/ct2/show/NCT02264548
Keywords: Primary tumour, Renal cell, Metastatic, Stereotactic ablative radiotherapy
Background
Metastatic renal cell carcinoma (mRCC) represents one of
the few clinical scenarios in which randomized evidence
supports aggressive primary tumour control via cytoreduc-
tive nephrectomy (CN), as this is associated with improved
overall survival when followed by interferon-based systemic
therapy [1, 2]. Likewise, non-randomized evidence in the
era of tyrosine kinase inhibitors (TKI) also supports a sur-
vival benefit of CN in select mRCC patients [3, 4] although
recent evidence supports superior overall survival with up-
front TKI and deferred CN vs. immediate CN [5]. However,
rates of CN have declined in the TKI era [6, 7]; moreover,
poor-PS and poor-risk patients do not benefit from CN [4]
as a result of greater post-surgical morbidity [8].
Stereotactic ablative radiotherapy (SABR) is emerging as
an effective ablative modality for renal tumours. Although
RCC is considered resistant to standard fractionation radio-
therapy [9], hypofractionated radiotherapy yields histologic
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tumour ablation [10, 11], and clinically, SABR is highly
effective in treating RCC oligometastases and can postpone
or obviate the need for systemic therapy in some instances
[12, 13]. Likewise, SABR is also an emerging ablative
modality for primary RCC tumours, achieving high rates of
local control with minimal toxicity [14, 15]. In a recent
multi-institutional pooled analysis conducted by the
International Radiosurgery Oncology Consortium for
Kidney (IROCK), 223 patients were treated with SABR
targeting RCC primary tumours, yielding a local control
rate of 97.8% at 2 years with CTCAE ≥ Gr. 3 toxicity
rate of 1.3% [16]. While alternative ablative therapies
such as cryotherapy or radiofrequency ablation can tar-
get primary tumours, these are limited by size (< 4 cm)
and location (peripheral) [17, 18].
We hypothesized that SABR may represent an alterna-
tive ablative modality for those patients who may other-
wise have benefited from cytoreductive nephrectomy, but
are medically inoperable or have unresectable primary
tumours. Moreover, given recent evidence that SABR may
stimulate anti-tumour immunity to increase sensitivity to
contemporary immunotherapy [19–21], there is strong
rationale to establish the safety of this technique, permit-
ting its combination with immune checkpoint inhibitors
to potentially enhance their effectiveness.
We previously published our retrospective experience
[22] wherein SABR safely and tolerably treated unconven-
tionally large renal tumours (median 9.5 cm, above the con-
census 5–8 cm upper limit of size [23]). Here we report the
results of a prospective trial of 5-fraction SABR targeting
the tumour-bearing kidney in mRCC. The primary end-
point was safety/toxicity and secondary endpoints included
renal function, patient-reported quality of life, tumour
response, and overall survival.
Methods
Patient Eligibility
In this ethics board-approved protocol (Western University
REB# 15680), eligible patients were ≥ 18 years old, were
diagnosed with stage IV, biopsy-confirmed RCC, and were
deemed medically inoperable or harbored an unresectable
primary tumour. Operability was assessed by a urologic on-
cologist (all patients were reviewed in a multi-disciplinary
clinic including a surgeon, radiation oncologist, and med-
ical oncologist). Patients could be enrolled regardless of
systemic therapy status and could receive SABR before or
after. Enrolled patients underwent detailed pre-screening
including baseline performance status and QoL assessment,
bloodwork, renal perfusion scan, and CT imaging. Those
with bilateral renal involvement, poor baseline renal func-
tion (creatinine clearance < 50 mL/min or < 40% flow to the
contralateral kidney on renal perfusion scan), non-RCC
histology, or life expectancy < 8 weeks were excluded. Pa-
tients receiving systemic therapy were included if treatment
was discontinued at least 2 weeks prior to SABR. Detailed
inclusion and exclusion criteria are provided on Clinical-
Trials.gov (NCT02264548).
Dose Escalation Protocol
The primary endpoint of this trial was safety/toxicity,
evaluated via the dose escalation cohort schema depicted
in Fig. 1. Each dose cohort was monitored during treat-
ment and in follow-up for dose limiting toxicities
(DLTs), defined as any CTCAE v 3.0 grade 3, 4, or 5 tox-
icity event that was definitely/probably/possibly related
to treatment. Recruitment of at least 3 patients to each
dose level (25, 30, 35, and 40 Gy in 5 daily fractions) was
planned. Advancement to the subsequent dose level was
permitted in the absence of a DLT up to 4 weeks post-
SABR. If a DLT event occurred in a cohort, that dose
level was repeated with 3 additional patients. If no fur-
ther DLTs occurred in the repeat cohort, recruitment to
the next dose level was permitted. The maximum toler-
ated dose (MTD) was reached if a second DLT occurred.
Due to a single DLT that occurred in the 30 Gy cohort,
a repeat cohort at that dose level was recruited. MTD for
this trial was reached when two DLT events were reported
in the 35 Gy cohort. Thus, no patients were recruited to
the 40 Gy cohort.
Treatment Technique
All enrolled patients were immobilized in a supine position
using a vacuum body mould as per institutional standards.
Motion control was achieved using four-dimensional CT
simulation wherein images were obtained at all phases of
the respiratory cycle to generate a composite integrated
target volume. OARs were contoured (without expansion
for planning risk volume (PRV)) and dose limited to these
structures based on established constraints [23, 24]. The
Fig. 1 Study Design. DLT – dose limiting toxicity; MTD – maximum
tolerated dose
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clinical target volume (CTV) included the primary tumour
and ipsilateral kidney to recapitulate a cytoreductive neph-
rectomy. The initial planning target volume (PTV-I) was
defined as the CTV with a 5 mm expansion in all three
dimensions, whereas the final PTV (PTV-F) was a compro-
mised PTV generated by subtracting any small bowel OAR
volume from the PTV-I (Additional file 1: Figure S1). Dose
was prescribed to the PTV-F.
Follow-up and Evaluation of Clinical Outcomes
Patients were monitored for adverse events on each treat-
ment day, then at 4, 8, and 12 weeks, and subsequently at
6-month intervals thereafter. Follow-up visits included
clinical assessment of toxicity using the Common Termin-
ology Criteria for Adverse Events version 3.0 (CTCAE
v4.0), QoL (FACT-G & FACT-KSI) and general symptom
assessment (ESAS) using standard questionnaires, blood-
work (CBC, electrolytes, urea, creatinine, calcium, albu-
min, liver enzymes, bilirubin, alkaline phosphatase) and
urinalysis. Pre- and post-SABR creatinine clearance (CrCl)
was calculated using the Cockroft-Gault equation and
glomerular filtration rate (GFR) measured using nuclear
medicine renal perfusion scans. Post-SABR CT scans were
performed at 4, 8, and 12 weeks and then at 6 month
intervals post-SABR to assess tumour response.
Statistical Analysis
Descriptive statistics were generated for baseline patient
and disease characteristics. The change in creatinine CrCl,
GFR, or QoL scores pre- and post-SABR were evaluated
using the Wilcoxon signed rank test. A Kaplan-Meier esti-
mate of overall survival including 95% confidence bands
was generated for all patients. All statistical analysis was
performed using SAS version 9.4 software (SAS institute,
Cary, NC), using 2-sided statistical testing at the 0.05
significance level.
Results
Patient and Disease Characteristics
From July 2009 to June 2016, 13 patients were enrolled in
the trial beginning at the 25 Gy dose level and proceeding
as depicted in Fig. 1. One patient from the 25 Gy cohort
was lost to follow-up prior to the first post-treatment visit
and thus was excluded. No acute toxicities were recorded
for this patient while on treatment. As summarized in
Table 1, the remaining 12 patients were of median age
66.8 years (range: 55–85), median KPS of 70% (40–90%),
and were mostly of ‘Intermediate’ (66.7%) or ‘Poor’ (25%)
International Metastatic Renal Cell Carcinoma Database
Consortium (IMDC) prognostic class [25]. The majority of
tumours were T2-T4 (91.7%), biopsy-proven RCC (clear cell
histology in 75%), and 8.7 cm median size (4.8–13.8). One
patient’s tumour histology was “poorly differentiated carcin-
oma” but was deemed eligible given the clinical context.
Table 1 Patient Characteristics (N = 12)
Characteristic Value
Age at diagnosis – median (range) 66.8 (55.0–85.1)
Male – n (%) 7 (58.3)
Laterality – n (%)
Left Kidney 4 (33.3)
Right Kidney 8 (66.7)
Histology – n (%)






Lymph nodes 5 (41.7)
Brain 3 (25)
Otherc 4 (33.3)
Karnofsky Performance Status – median (range) 70 (40–90)
Karnofsky Performance Status – n (%)
≥ 80% 5 (41.7)
< 80% 7 (58.3)









Systemic Therapy Type – n (%)
None 6 (50)
Pazopanib or Sunitinib 5 (41.7)
Temsirolimus or Everolimus 2 (16.7)
SABR Treatment Technique – n (%)
VMAT 7 (58.3)
TOMO 5 (41.7)




Primary tumor sized (cm) – median (range) 8.7 (4.8–13.8)
Actuarial median follow-up (months)e - median (95% CI) 22 (4.63, N/A)
IMDC: International Metastatic Renal Cell Carcinoma Database
Consortium, SABR: stereotactic ablative radiotherapy, CI: confidence
interval, TOMO: helical tomotherapy, IMRT: intensity modulated
radiotherap. aPoorly-differentiated carcinoma (n = 1); bCategories not
mutually-exclusive; cKidney (n = 1), liver (n = 2), left adrenal (n = 1);
dLongest tumor dimension on CT scan; eReverse
Kaplan-Meier Method
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Median CTV and PTV-F were 535.0 cm3 (288.2–883.5)
and 763.1 cm3 (264.9–1234.4), respectively. Distant metas-
tases occurred most commonly in lung, bone, and brain.
Six of the 12 patients received systemic therapy pre-SABR
(1), post-SABR (4), or both (1). Systemic therapy was initi-
ated any time after SABR (given a minimum 2 week wash-
out period) as indicated for progression of metastatic
disease. Additional file 2: Figure S2 depicts the timing of
systemic therapy, per patient, relative to completion of
SABR. Six patients did not receive systemic therapy.
Treatment Parameters
Doses to treatment volumes and OAR are listed by indi-
vidual patient in Additional file 3: Table S1. Favorable
coverage of treatment volumes was achieved, with ≥95%
of the CTV and PTV-F receiving 95% of the prescribed
dose in all trial patients. The PTV-I (median 798.9 cm3,
315.1–1265.5) was compromised by a median (range) of
4.0% (0.02–17.9) to exclude small bowel. The median
V95 for the PTV-I was 97.5% (80.1–99.9). Plans were
optimized such that OAR doses were limited to
commonly-accepted constraints for 5-fraction abdominal
SABR [23, 24] as listed in Additional file 3: Table S2.
Toxicity
Patients were recruited to dose cohorts according to an a
priori dose-escalation scheme (Fig. 1). Demographic infor-
mation, disease characteristics, and treatment details are
listed by patient in Table 2. Overall, treatment was safe
and well-tolerated. Table 3 lists all reported toxicity events
that were possibly, probably, or definitely treatment-
related. Three grade 3 events (possibly, probably, or defin-
itely treatment-related) were reported: 2 fatigue (probably
and definitely related) and 1 bone pain (possibly related).
A large proportion of grade 1 & 2 toxicities were gastro-
intestinal, including altered taste, nausea, and vomiting
(reported in 75% of patients). Fatigue ≥ grade 1 was
reported in 50% of patients. All toxicities were effectively
managed with supportive measures. There were no grade 4
or 5 treatment-related events. Patient 9 suffered an unre-
lated grade 4 pneumonia and patient 6 succumbed to unre-
lated grade 5 dyspnea secondary to pulmonary embolus.
Renal Function
Overall renal function was largely preserved following renal
SABR. Nuclear medicine scans revealed reductions in the
proportion of function of the ipsilateral kidney as well as in
measured GFR in most patients (Fig. 2a). No significant
reduction in GFR was observed at 12 weeks post-SABR
[median 72.7 (range: 56.0–109.9) vs. 62.8 (52.3–74.04) mL/
min/1.73m2, p = 0.125]. Likewise, pre- and post-SABR (at
last follow-up) creatinine clearances were not significantly
different [median 98.1 (range: 40.1–193) vs. 88.1 (53.1–139)
mL/min, p = 0.164] (Fig. 2b). No patients required dialysis.
Quality of Life (QoL)
Patient-reported quality of life was assessed by Functional
Assessment of Cancer Therapy (FACT) questionnaires at
baseline (n = 12) and at scheduled follow-up visits (n =
10). QoL declined with respect to physical well-being (p =
0.016), but remained unchanged in the functional, social
and emotional domains as well as overall QoL (p > 0.05).
Likewise, QoL scores for a kidney-specific index (FACT-
KSI) were similar pre- and post-SABR (p > 0.05). Results
are summarized in Additional file 3: Table S3.
Table 2 Summary of patient and disease characteristics by individual patient (N = 12)
Characteristic Mediand Patient
1 2 3 4 5 6 7 8 9 10 11 12
Age 66.8 69 59 85 54 57 61 81 70 76 82 61 64
T Stage – T3c T2a T3b T2b T3c T2b T2a T4 T2a T2a T3a T1b
N Stage – N0 NX N0 NX N1 NX N1 N1 N1 N0 N1 N0
Laterality – L R R R R R R R R L L L
Tumor Size (cm)a 8.7 9.3 7 8.9 11.9 11.2 13.8 7.3 10 7.9 7.5 9.8 4.8
Radiation Dose (Gy) / Fractions – 25/5 25/5 25/5 30/5 30/5 30/5 30/5 30/5 35/5 30/5 35/5 35/5
Δ CrCl (mL/min.) −13.5 −13.5 35.9 −12.1 −4.6 NR −48.2 NR NR −36.6 −24.7 −54 17.5
Local Response (%)b −17.3 −11.8 −17.1 −30.3 −25.2 −25.9 −5.8 NR NR −54.4c + 5.3 −17.5 −14.6
Time to Systemic Progression (months) 3.9d 4.34 0.7 10.9 20.5 0.6 0.9 0.8 0.5 12.2 15.0 5.2 3.9
Systemic Therapy – P P – P,E – T – – – – S S
Survival (months) 6.7d 4.9 10.2 16.4 43.6 1.5 3.2 1.3 2.4 13.6 22e 6.7 4.6
L: left kidney, R: right kidney, HT – helical tomotherapy, IMRT: intensity modulated radiotherapy, VMAT: volumetric arc therapy, NR: not reported, CrCl: Creatinine
clearance, Δ - change, P: pazopanib, E: everolimus, T: temsirolimus, S: sunitinib. aLongest tumor dimension on CT scan; bMaximal reduction (−) or increase (+) in
primary renal tumor size following SABR, expressed as percent of initial size; cPt. 9 also underwent renal embolization (post-SABR) for refractory hematuria;
dMedian overall survival and time to systemic progression calculated using Kaplan-Meier method (95% CIs: 1.48–16.43 and 0.7–10.7, respectively); eAlive at
last follow-up
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Tumour Response and Overall Survival
Despite local disease stability with a median tumour size
reduction of − 17.3% (range: + 5.3 to − 54.4) at a median
follow-up time of 5.3 months (95% CI: 1.1–9.4), all patients
progressed systemically (Fig. 3c). Overall survival (95% CI)
at 6, 12, and 24 months was 57.1% (25.4–79.6), 38.1% (12.1–
64.4), and 19.1% (3.0–45.6), respectively (Fig. 3d). Median
(95% CI) overall survival was 6.7 months (1.5–16.4). Crude
median follow-up (range) was 5.8 months (1.4–43.6).
Discussion
Here we report on the first prospective trial of renal-
ablative SABR as an alternative to cytoreductive nephrec-
tomy in non-operable patients with mRCC. Building on
our institutional experience of this technique in a case-
series of unconventionally large renal tumours [22], this
phase I trial evaluated cytoreductive SABR targeting the
whole ipsilateral kidney, in essence to recapitulate the
effects of debulking nephrectomy.
Our key findings include the safe delivery of 35 Gy in 5
fractions with minimal toxicity, favorable renal outcomes,
preserved quality of life, and local disease stability in all
cases where longitudinal imaging was available. Our trial
design deliberately employed a conservative fractionation
schedule so as to limit dose to organs at risk and thus
minimize toxicity in this metastatic patient population
with poor PS. A five-fraction regimen is in keeping with
multi-fraction SABR protocols which often use 3–5 frac-
tions [16, 23]. With respect to renal function, while no
statistically significant decline was observed post-SABR,
decreases in mean CrCl and GFR were noted (− 10 mL/
min and − 9.9 mL/min/1.73m2, respectively). These differ-
ences are relatively mild in the context of estimated
decline in eGFR following radical nephrectomy: −
22.4 mL/min/1.73m2 based on a recent systematic review
and meta-analysis (27 articles; 3719 patients) [26].
We hypothesized that primary renal SABR as an alterna-
tive to cytoreductive nephrectomy holds promise for several
reasons. First, as tyrosine-kinase inhibitors (TKIs) are con-
sidered the standard of care in mRCC, the initiation of
these agents would be delayed following a nephrectomy
owing to surgical healing. In contrast, SABR is a convenient
non-invasive outpatient procedure that, in other disease
sites, requires only a short delay (i.e. 2 weeks) prior to the
initiation of a pharmacologic agent. In fact, one prospective
study suggests that SABR to an extra-renal target with
Table 3 All Possible Treatment-Related Toxicity Eventsa (N = 12)









Fatigue 2 10 2
Pain - Abdominal 5
Pain - Bone 1 1
Weakness 2 1







aExpressed as no. of events using CTCAE v3.0 and including both acute (on
treatment) and late (reported in follow-up ≥4 weeks post-SABR) bFrequency
& urgency
Fig. 2 Renal Function. a Functional contribution of both kidneys pre-
and 12 weeks post-SABR with corresponding measured GFR values listed
above each bar. Numbered bars indicate % contribution from ipsilateral
kidney. b Comparison of creatinine clearance (CrCl) calculated using the
Cockroft-Gault equation before and after stereotactic ablative radiotherapy
(SABR) for patients with available pre- and post-SABR data (n = 9). P-value
reported from the Wilcoxon signed-rank test
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concomitant pazopanib is safe [27]. Second, many primary
targets in mRCC are technically inoperable due to tumour
size or proximity to the collecting vessels and ureter.
SABR can be targeted precisely to access any location
within the affected kidney and dose can be sculpted within
organ-at-risk tolerance. Third, SABR is inherently tissue-
sparing, whereas a nephrectomy may result in decline of
pre-existing renal dysfunction or even de novo chronic
kidney disease.
Finally, SABR holds promise for mRCC particularly in
the era of contemporary immunotherapy. Despite the
excitement surrounding checkpoint inhibition, response
rates appear to reach a ceiling of 20–40% [28]; for nivolu-
mab, which has been approved for second-line treatment
of mRCC, the response rate is 25% [29]. Thus, it is
essential to explore strategies to extend the benefits of
these agents to additional patients. SABR has emerged as
one such strategy since its mechanism of action partly
involves inciting anti-tumour immune activation [30, 31]
as well as abscopal (out-of-field) effects in mRCC and
other malignancies [32, 33] - a phenomenon also thought
to involve systemic anti-tumour immunity [19–21].
Interestingly, PD-1 inhibition can increase the frequency
of radiotherapy-induced abscopal effects in a xenograft
mouse model of RCC [20]. Clinically, several case reports
have emerged demonstrating improved systemic re-
sponses when radiotherapy and checkpoint inhibition are
combined [34–37]. Singh et al. recently demonstrated
local anti-tumour immune activation in renal tumours
following single-fraction SABR [38]. Our demonstration
of the safety and tolerability of SABR in mRCC therefore
justifies the combination SABR with immune checkpoint
inhibition as a rational therapeutic strategy worthy of
further investigation.
The limitations of this study include its small sample
size at a single institution. Also, given the short median
OS and consequently short follow-up in this trial (crude
median follow-up: 5.8 months), the full range and severity
of late toxicities may be under-appreciated. Another limi-
tation is the heterogeneity in systemic treatment among
the patients on this trial: specifically, the agents used and
their timing was variable. Moreover, 50% of patients were
not fit enough to receive systemic therapy. The OS of
6.7 months were relatively short and probably reflect, in
part, the heterogeneity in patient selection and treatment;
more careful patient selection and uniform treatment
would likely be associated with better survival outcomes.
Finally, it is unclear what the optimal local response
assessment tool is in this setting, as distinguishing re-
sponse from post-treatment effect remains challenging.
The strengths of this study are its prospective design with
a priori dose-escalation scheme and its novelty; to our
knowledge, no other institution has evaluated post-SABR
outcomes in the mRCC setting as we have done here.
Conclusion
We observed low toxicity with SABR to a dose of 35Gy
in 5 fractions targeted to the primary tumour and ipsilat-
eral kidney. Exploration of this regimen as an alternative
to CN in larger prospective trials with up-front cytore-
ductive SABR followed by systemic therapy appears feas-
ible based on our results. Additionally, tumour-targeted
SABR could allow further dose-escalation while sparing
normal renal parenchyma. Given the hypothesized
immune activation induced by SABR, combining renal
SABR with immune checkpoint inhibition in mRCC
could be a particularly interesting approach and a multi-
institution phase II trial is planned.
Additional files
Additional file 1: Figure S1. Example of treatment planning volumes. To
facilitate treatment of large PTVs, the initial PTV (teal outline) was trimmed
in areas of overlap (green colorwash) with organs at risk - particularly small
bowel (purple colorwash) – trimmed to generate a final PTV (red colorwash).
(JPEG 127 kb)
Additional file 2: Figure S2. Clinical Course by Individual Patient. Time
from initial radiologic diagnosis to death or last follow-up for each patient
(y-axis intersect: SABR completion date). Duration and type of systemic
Fig. 3 Treatment Response and Survival. a Abdominal and b thoracic
coronal CT slices from patient 11 pre-SABR (left) and 7 months post-SABR
(right). c Tumour size expressed as percent change in longest tumour
dimension. Horizontal dotted lines mark a 20% increase and 30% decrease
in size. Patient 9 (dotted/dashed line) also underwent renal embolization
for refractory hematuria on day 27 post-SABR. d Kaplan-Meier plot of
overall survival with 95% confidence bands (n =12)
Correa et al. Radiation Oncology  (2018) 13:47 Page 6 of 8
therapy, additional local therapies, and date of systemic progression are
indicated. 1Palliative embolization of bulky pelvic metastasis followed by
hip replacement surgery; 2Palliative radiotherapy (20 Gy/5) following
hip replacement; 3Renal artery embolization for refractory hematuria;
4Palliative radiotherapy to painful bony metastasis (shoulder). (JPEG 111 kb)
Additional file 3: Table S1. Target Dose and Volume Data by Individual
Patient. CTV- clinical target volume; PTV-I – initial planning target volume;
PTF-F – final planning target volume; NR – not reported. Table S2. Organ
at Risk (OAR) Constraints and Doses (cGy). D1–99% of the contoured volume
receives this dose or less; D33–67% of the contoured volume receives this
dose or less; *Small bowel dose constraints were exceeded in Patients 2 & 6.
Patient 2 reported no toxicity whatsoever and Patient 6 reported only grade
1 emesis. Table S3. Summary of Quality of Life (QoL) Data at Baseline and
Last Available Follow-Up (N = 12*). (DOCX 28 kb)
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